Would you get a one-time genetic modification such that you'd never have to take a GLP-1 drug for weight loss ever again?

University of Osaka researchers used genome editing to program mouse liver cells to produce exenatide, a weight-loss drug.

Weight-loss drugs have surged in popularity, promising rapid results with regular injections. Now, researchers from Japan ...

Adults with type 1 diabetes on multiple daily injection therapy saw no benefit in glycemic measures when adding on preprandial injections of short-acting exenatide, according to findings from a ...

Researchers create a one-time genome editing introducing a GLP-1 receptor agonist, resulting in long-term appetite ...

Exenatide is a GLP-1-like (analog) medication primarily prescribed to treat Type 2 diabetes, approved by the U.S. Food and Drug Administration in 2005.

Exenatide is the active ingredient in BYETTA(R) (exenatide) injection, which is currently available in the U.S. and in many countries worldwide for people with type 2 diabetes who are unable to ...

The Exenatide-PD3 trial randomly assigned 194 Parkinson's patients who were on dopaminergic treatment to either 2 mg of extended-release exenatide by subcutaneous pen injection once weekly (97 ...

Vivani Medical has commenced the first-in-human, randomised trial, LIBERATE-1, by initiating screening and enrolment to assess the pharmacokinetic and safety profile of its exenatide NanoPortal ...

Treatment with once-weekly exenatide was not associated with improvements in patients with Parkinson disease, according to findings from a study published in The Lancet.. Exenatide, a glucagon ...

A study in the United Kingdom involved 194 people with Parkinson’s disease who were randomly assigned to inject themselves once a week with exenatide, marketed as Byetta, or with a placebo.